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Abstract
During natural HIV infection, an array of host receptors are thought to influence virus attachment
and the kinetics of infection. In this study, to probe the interactions of HIV envelope (Env) with
various receptors, we assessed the inhibitory properties of various anti-Env monoclonal antibodies
(mAbs) in binding assays. To assist in detecting Env in attachment assays, we generated Fc fusions
of full-length wild-type gp120 and several variable loop-deleted gp120s. Through investigation of
the inhibition of Env binding to cell lines expressing CD4, CCR5, DC-SIGN, syndecans or
combinations thereof, we found that the broadly neutralizing mAb, 2G12, directed to a unique
carbohydrate epitope of gp120, inhibited Env-CCR5 binding, partially inhibited Env-DC-SIGN
binding, but had no effect on Env-syndecan association. Furthermore, 2G12 inhibited Env
attachment to primary monocyte-derived dendritic cells, that expressed CD4 and CCR5 primary
HIV receptors, as well as DC-SIGN, and suggested that the dual activities of 2G12 could be valuable
in vivo for inhibiting initial virus dissemination and propagation.
Background
The envelope glycoprotein (Env) of HIV mediates virus
fusion and entry into susceptible cells [1]. Env consists of
a trimer of gp120/gp41 heterodimers, in which gp120 is
the external surface subunit (SU) responsible for engaging
cellular receptors and gp41 is the transmembrane subunit
(TM) that mediates membrane fusion [1]. Infection
occurs after sequential interactions of gp120 with cellular
CD4 and a coreceptor, usually CCR5 or CXCR4. Because
of its role in the infection process, Env is the principle tar-
get for neutralizing antibodies (nAbs). Unfortunately,
very little progress has been made to date in developing
vaccines able to elicit nAbs. The hope that one day these
efforts may be fruitful is provided by the finding of a few
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broadly and potently neutralizing mAbs. These include
MAb b12, which binds to an epitope overlapping the CD4
binding site of gp120 [2]; 2G12, which binds a cluster of
high mannose residues on the immunologically "silent"
face of gp120 [3-7]; and Z13, 2F5 and 4E10, which recog-
nize adjacent epitopes in the membrane proximal external
region of gp41 [8-13]. Understanding the activities of
these naturally occurring nAbs may yield clues as to how
to best present their epitopes in vaccines.
The first step in the HIV life cycle is attachment to target
cells. Attachment can be achieved by the primary recep-
tors that the virus uses to gain entry to cells. Indeed, for
HIV strains adapted for growth in T cell lines, neutraliza-
tion appears to be based entirely on inhibition of attach-
ment [14-17]. However, for other cell targets, alternative
surface molecules can facilitate virus adsorption and mod-
ulate the efficiency of the entry process [14,18-21]. For
example, neutralization by a blockade of CD4 binding
does not impair virus attachment to peripheral blood
mononuclear cells (PBMCs) [22], suggesting the involve-
ment of interactions other than gp120-CD4 in initial virus
attachment [15,18,23]. Furthermore, due to low CD4
expression, HIV attachment to macrophages and dendritic
cells is completely dependent on supplementary receptors
[19].
Three main classes of HIV attachment receptors have been
found to modulate HIV entry via CD4 and chemokine
receptors: LFA-1 [24], DC-SIGN (dendritic cell-specific
intercellular adhesion molecule-3 grabbing nonintegrin)
[25] and heparan sulfate proteoglycans (HSPGs) [14].
Though attachment can involve molecules other than Env
that are incorporated into the virus membrane [26-30], as
exemplified by LFA-1-ICAM-1, from an intervention per-
spective, interactions involving Env are of greater interest.
DC-SIGN is a mannose-specific, calcium-dependent (C-
type) lectin specifically expressed on dendritic cells (DCs)
that plays a key role in the development of immune
responses to highly glycosylated viral pathogens, includ-
ing primate lentiviruses [25,31]. DC-SIGN captures virus
via through N-linked high mannose structures on gp120,
after which the dendritic cell transports the virus to sec-
ondary lymphoid tissue. In normal circumstances, this
would facilitate a strong antiviral immune response.
However, for HIV-1, transport to lymph nodes has the
unfortunate side effect of presenting the virus to primary
CD4+ T cell targets, facilitating trans-infection and virus
dissemination throughout the body [21,25,31-34]. Over-
all, the very high (low nanomolar) affinity of DC-SIGN
for gp120 [35,36] and the presence of DCs in mucosal sur-
faces suggest a key role for DC-SIGN in virus transfer from
the submucosa to secondary lymphoid organs during sex-
ual transmission [37].
HSPGs are transmembrane receptors expressed in high
concentrations on the surface of adherent cells (e.g. epi-
thelial cells, endothelial cells and macrophages), but not
suspension cells (e.g. T-lymphocytes). HSPGs were first
reported to mediate HIV attachment to the adherent cell
line, HeLa [17,38,39]. Though fresh macrophages gener-
ally express low levels of HSPGs, a single family of HSPGs,
the syndecans, present on monocyte-derived macro-
phages (MDMs) have been shown to mediate HIV bind-
ing [19,20]. Syndecans may also contribute to attachment
to PBMCs, despite relatively low expression, [18,40].
Although syndecans can bind HIV virions lacking Env, in
part through binding to cyclophilin A present on the virus
surface [19,41], most virus attachment appears to be
gp120-specific, especially for PBMC-produced virus
[17,20,42]. Just as DC-SIGN-expressing DCs capture and
transport virus to the lymph node and propagate CD4 T
cell infection in trans, so can syndecan-expressing macro-
phages. These molecules can also facilitate infection in cis.
That is, when expressed on cells that also bear CD4 and
coreceptor, they markedly enhance virus entry. In this
way, DC-SIGN and HSPGs effectively increase the tropism
of HIV by concentrating virus where primary receptor lev-
els are otherwise below the threshold required for efficient
entry, thereby promoting virus dissemination [20,31].
The nature of the interactions of CD4, CCR5, DC-SIGN
and HSPGs with HIV-1 Env during infection have impli-
cations for intervention strategies. Blocking Env-based
virus attachment to any of these cellular receptors would
provide a rationale for new microbicide or vaccine strat-
egy. Understanding how Env interacts with these recep-
tors and, moreover, how presently available monoclonal
antibodies (mAbs) inhibit these interactions would be a
step toward this goal. Studies to date have revealed that
mAb b12 blocks gp120-CD4 binding [2]; mAbs directed
to gp120 epitopes that are induced by sCD4, as well as V3
mAbs, interfere with CCR5 binding [43-45]; and 2F5 and
4E10 appear to prevent fusion events that occur after CD4
and CCR5 binding, though they may also bind to Env in
its native form [12,46]. In comparison, relatively little is
known about how these mAbs might block virus attach-
ment to various cells, and indeed what Env determinants
are important (12). This is due in part to difficulties in
unequivocally measuring virus-cell binding. For example,
measuring mAb inhibition of virus attachment is compli-
cated when the virus is also neutralized by the mAb. Thus,
methods to measure attachment have tended to rely on
detecting surrogates of virus binding, such as virus-associ-
ated p24 or surface HLA-DR [16,19,47,48], or the use of
immunofluorescent-labeled virus [14,49]. Measuring
attachment is further complicated by the differential
expression of attachment molecules on target cells and
differential incorporation of adhesion molecules on the
virus particle, depending on the producer cells. Thus,Retrovirology 2006, 3:39 http://www.retrovirology.com/content/3/1/39
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when investigating virus-cell attachment, a careful consid-
eration of how expression of surface proteins might differ
between various virus producer and target cells is crucial
[20].
In light of the difficulties in assaying virus attachment,
investigating Env-receptor interactions using monomeric
gp120 offers a convenient alternative. Although gp120
monomers may not fully recapitulate the properties of oli-
gomeric Env on virus, gp120 binding studies provide a
useful adjunct to whole virus attachment studies by une-
quivocally measuring Env's contribution in the absence of
any confounding background attachment by virus-cell
interactions not involving Env. Nevertheless, soluble Env
binding assays come with their own technical challenges.
For example, Env binding has been detected either by a
radioactive readout [50] or by lysis of target cells, gp120
immunoprecipitation and autoradiography [51-53].
Binding assays would, therefore, be simplified by using
gp120 that is directly tagged to simplify its detection. Pre-
viously, the Fc portion of IgG has been genetically fused to
several proteins of clinical interest, including cytokines
[54,55] and viral envelope proteins [56-59]. Not only
does Fc-fusion provide a very convenient way to express
and purify proteins of interest (using protein A or G), but
it also provides a convenient way to directly tag the pro-
tein of interest, avoiding any difficulties associated with
secondary detection methods.
Fc-Env chimeras have been previously used to assist tradi-
tional virus-cell binding assays to simplify the study of
Env attachment and Env-receptor interactions [36,60].
MAbs directed to the V3 loop and CD4-induced epitopes
were found to inhibit virus attachment to syndecans but
not to DC-SIGN [20]. We, and others previously used Fc-
gp120 chimeras to map the determinants of the V3 loop
important for attachment of virus to syndecan-expressing
cells [42]. Other ELISA data suggested a role for the V3
loop in DC-SIGN-gp120 binding [61]. However, this find-
ing is difficult to reconcile with the binding of V3 loop-
deleted gp120 to DC-SIGN [42,61].
Therefore, we used Fc-gp120 fusion proteins to probe Env
binding to cellular receptors and examine the abilities of
various mAbs to inhibit Env binding to various cell lines
with well-defined expression profiles of CD4, CCR5, DC-
SIGN and HSPGs. We focused on 2G12 because, com-
pared to other nAbs, relatively little is known about its
mechanism and also because its unusual carbohydrate
epitope does not overlap that of any other known anti-
gp120 mAb, suggesting that it may have a unique mode of
action [62]. To assess the in vivo relevance of our findings,
we also investigated mAb inhibition activities using pri-
mary monocyte-derived DCs (MDDCs) and peripheral
blood lympocytes (PBLs) as targets.
Results
Characterization of Fc-gp120 chimeras
Purified Fc-gp120 chimeras were first analyzed by SDS-
PAGE in non-reducing (Fig. 1A, left panel) and reducing
(Fig. 1A, right panel) conditions. Fc-gp120 WT dimers
have a molecular weight of ~290 kDa in non-reducing
conditions and ~145 kDa in reducing conditions. The var-
iable loop-deleted versions of Fc-gp120 behaved in a sim-
ilar manner. Thus Fc-gp120 chimeras exist as
homodimers, presumably stabilized by non-covalent
association of the Fc portion. To address whether linkage
of Fc to gp120 or dimerization affects gp120 conforma-
tion, Fc-gp120 chimeras were compared to monomeric
gp120WT, ∆V1V2V3 and an Fc fragment, by ELISA (Fig.
1B). MAb b12 and CD4-IgG2 bound equivalently to all of
the gp120-containing constructs. HIVIG and 2G12 bound
somewhat more weakly to constructs lacking the V3 loop.
As expected, the V3 loop-binding mAb 447-52D did not
recognize any of the ∆V3 gp120 proteins. Also as
expected, the V2-specific mAb, G3-4, did not recognize
constructs that lacked V1V2 loop domains. The CD4i
mAb 17b bound relatively weakly to the V3 loop-deleted
gp120s, but sCD4 restored high affinity CD4i mAb bind-
ing to all constructs. Overall, the ELISA data revealed sim-
ilar mAb binding patterns for full-length and variable
loop-deleted forms of Fc-gp120 dimers and gp120 mono-
mers. Therefore, Fc-gp120 fusion and dimerization had
little effect on gp120's immunochemical properties, vali-
dating them as useful tools for studying Env-receptor
interactions.
Fc-gp120 binding to cellular CD4 and its inhibition
We next analyzed Fc-gp120 binding to receptor-bearing
cell lines by FACS, initially using CEM cells expressing
CD4 but no coreceptor. We developed a competition for-
mat to measure inhibition of Fc-gp120 binding by pre-
incubating Fc-gp120 with graded concentrations of solu-
ble ligands (sCD4, b12 and 2G12). We found that sCD4
inhibited Fc-gp120 binding in a dose-dependent manner,
with nearly 100% inhibition at 10 µg/ml sCD4 for WT,
∆V3 and ∆V1V2 Fc-gp120 (Fig. 2A). Interestingly, the
competition efficiency was diminished for ∆V1V2V3 Fc-
gp120, with only 50% inhibition at 10 µg/ml sCD4. This
was unexpected, considering that ∆V1V2V3 was recog-
nized equivalently to the other Fc-gp120 chimeras by
CD4-IgG2 (Fig. 1C), but might stem from differences in
affinity of different forms of CD4 (sCD4, CD4-IgG2 and
cellular CD4) for Fc-gp120 ∆V1V2V3. We next investi-
gated other mAb inhibitors, ensuring that detection via
the Fc domain solely reflected Fc-gp120 binding, by using
Fab fragments. We found that the b12 Fab, directed to an
epitope overlapping the CD4 binding site, inhibited Fc-
gp120 binding, as expected (Fig. 2B). In contrast, 2G12
Fab did not efficiently inhibit Fc-gp120 binding to CEM
cells (Fig. 2C), suggesting that the mAb inhibits an eventRetrovirology 2006, 3:39 http://www.retrovirology.com/content/3/1/39
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after gp120-CD4 attachment. 2G12 was even weaker at
inhibiting the binding of V3 loop-deleted Fc-gp120s (∆V3
and ∆V1V2V3) to CD4+ cells (Fig. 2C), consistent with its
above noted inefficient binding to V3 loop-deleted Fc-
gp120s [63] (Fig. 1B).
Fc-gp120 binding to cellular CCR5 and its inhibition
Further investigation of the Fc-gp120/sCD4 complex
binding to CCR5+ cells, as expected, showed specific inhi-
bition by CCR5 binding molecules RANTES and TAK779
(Fig. 3A). Based on previous studies, inhibition of Fc-
gp120 binding to CCR5 might be expected by mAb
directed to CD4-induced epitopes [50,51] or the V3 loop
[44,64]. However, mAb 2G12 directed to a cluster of high
mannose oligosaccharides in the "silent domain" of
gp120 [4,5,7], is distinct from the domains so far directly
implicated in either CD4 and CCR5 binding [65,66] and,
therefore, neutralization is thought to occur by steric inhi-
bition [6,50]. Although 2G12 does not significantly inter-
fere with CD4-gp120 binding (Fig. 2), there have been
hints of a possible CCR5 blocking mechanism [50,67-69].
To further investigate, we examined 2G12's effect on Fc-
gp120-sCD4 complex binding to CCR5. We found that
2G12 inhibited this interaction (Fig. 3A), approaching
100% effectiveness at 25 µg/ml, consistent with the previ-
ously reported 2G12 IC90 neutralizing titer of ~5 µg/ml
against JR-CSF [60].
Although our previous experiments indicated that 2G12
does not interfere with Fc-gp120 binding to cellular CD4
(Fig. 2C), to rule out any direct competition between
2G12 and sCD4 in the CCR5 binding assay, we performed
additional inhibition assays using 1 µg/ml or 10 µg/ml of
sCD4 to form complexes with Fc-gp120 WT, with mAb
b12 as a control. As expected, higher concentrations of
sCD4 decreased the ability of b12 to inhibit binding of Fc-
gp120 to CCR5+ cells (Fig. 3B). In contrast, higher sCD4
concentrations did not diminish 2G12 blocking of the Fc-
gp120-sCD4 complex to CCR5+ cells, consistent with the
notion that 2G12 inhibits only the gp120-CCR5 interac-
tion (Fig. 3B).
To investigate whether our findings with Fc-gp120 are rel-
evant to virus bearing functional trimers, we examined
virus neutralization in standard and "post-CD4" formats
(Fig. 4). The standard neutralization format uses
Cf2.Th.CD4.CCR5 cells. The "post-CD4" format involves
pre-incubating virus with sCD4 and graded concentra-
tions of a nAb, then measuring residual infection of CD4
negative Cf2.Th.synCCR5 cells. Use of target cells express-
ing only CCR5 eliminated any potential competition
between cellular CD4 and sCD4. As expected, the positive
control mAb b12 neutralized effectively in the standard
format. However, it was approximately 2.5-fold less active
in the "post-CD4" format (Fig. 4A), consistent with b12
Design and production of the Fc-gp120 chimeras Figure 1
Design and production of the Fc-gp120 chimeras. Fc-
gp120 chimeras were constructed by fusing the C-terminus 
of human IgG1 Fc (H, CH2, CH3 domains) in-frame with the 
N-terminus of gp120JR-CSF. Full-length wild-type (WT) and 
∆V3, ∆V1V2 and ∆V1V2V3 forms of Fc-gp120 were 
expressed. A) SDS PAGE and Coomassie staining of purified 
Fc-gp120 chimeras under reducing and non-reducing condi-
tions. B) ELISA assays comparing mAb binding to Fc-gp120 
chimeras, an Fc control and monomeric full-length gp120 
WT and ∆V1V2V3. Symbols are as indicated. Results are rep-
resentative of two independent assays.
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binding an epitope that overlaps the CD4 binding site on
gp120. The sCD4 protein (used at 10 µg/ml) apparently
does not completely block b12 neutralization, presuma-
bly because at higher b12 concentrations, sCD4 might be
displaced. In contrast, mAb X5 did not neutralize effec-
tively in the standard format, but showed extremely
potent activity in the "post-CD4" format (Fig. 4B). This is
consistent with the notion that the X5 epitope, overlap-
ping the CCR5 binding site of gp120, is cryptic in the
native form of gp120, but becomes exposed and induced
upon CD4 binding. A third pattern was observed with
mAb 2G12, which neutralized the virus in both formats,
with an approximately 4-fold greater activity in the post-
CD4 format. The difference was not as dramatic as
observed with X5, implying that the 2G12 epitope is not
induced by CD4 binding, but rather that it is impartial.
MAb 2G12, therefore, appears to neutralize HIV-1 by
steric interference of gp120-CCR5 binding, consistent
with CCR5 blocking assays using Fc-gp120 (Fig. 3), vali-
dating Fc-gp120 chimeras as adjuncts for further investi-
gating Env-receptor interactions.
Fc-gp120 binding to DC-SIGN and HSPGs and its inhibition
DC-SIGN has been reported to recognize high mannose
residues on gp120 [4,5,7]. In a serie of experiments, we
initially investigated DC-SIGN-gp120 interaction using
Fc-gp120 chimeras and DC-SIGN-expressing CHO
pgsA745 target cells deficient in glycosaminoglycan bio-
synthesis and, therefore, HSPG expression. Elimination of
HSPG expression was important, considering that high
affinity gp120-HSPG binding might confound any true
measurement of gp120-DC-SIGN binding. We found that
all of the Fc-gp120 chimeras bound these cells (Fig. 5A,
data shown only for Fc-gp120 WT). Fc-gp120 binding to
DC-SIGN was specific, since Fc alone did not bind, and Fc-
gp120 binding could be blocked by mannan (Fig. 5A) and
EGTA (data not shown). Since 2G12 also recognizes ter-
minal mannose residues [60], we wondered if it might
also inhibit Fc-gp120-DC-SIGN binding. We found that
25 µg/ml 2G12 IgG inhibited DC-SIGN-Fc-gp120 WT to
~75% (Fig. 5A). The specificity of this inhibition was fur-
ther supported by the observation that 2G12 Fab and IgG
showed similar degrees of competition. Thus, in addition
to gp120-coreceptor blocking, 2G12 appears to also
inhibit gp120-DC-SIGN interaction. Similar results were
observed with the variable loop-deleted Fc-gp120 chime-
ras (data not shown).
Our results contrast with a previous report that 2G12 had
no effect on gp120-Fc binding to DC-SIGN-expressing
BC7 cells or on virus binding to DC-SIGN-expressing
293T cells [60]. Several differences between ours and the
previous study might explain this discrepancy: i) we used
a gp120 chimera in which Fc is positioned at the N-termi-
nus of gp120 (Fc-gp120), whereas Hong et al. used a chi-
Binding of Fc-gp120 chimeras to cellular CD4 Figure 2
Binding of Fc-gp120 chimeras to cellular CD4. Inhibi-
tion of binding of Fc-gp120 chimeras to CEM-CD4 cells by 
(A) sCD4, (B) Fab b12 or (C) Fab 2G12. Inhibition of binding 
was assessed by FACS analysis and is expressed as % binding 
inhibition. Results are means of triplicate determinations.
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mera with the Fc domain fused at the C-terminus of gp120
(gp120-Fc); ii) the previous analysis was performed using
293T cells that, characteristic of adherent cell lines,
express relatively high levels of HSPGs that can also bind
gp120 and might, therefore, have masked the inhibitory
effect of 2G12 on gp120 binding to DC-SIGN; iii) pro-
ducer cell glycosylation machinery may influence gp120
glycan structure and neutralization sensitivity. Our Fc-
gp120 chimeras were produced in CHO cells, whereas
previously, wild-type gp120-Fc was produced in 293T
cells [60]. Furthermore, gp120 fusion with Fc at the N-ter-
minus rather than the C-terminus leads to more uniform
glycosylation; iv) our gp120 chimeras were protein A puri-
fied, whereas Hong et al. used unpurified gp120-Fc super-
natants.
To investigate point i), whether the position of Fc influ-
ences 2G12 inhibition, we assessed the ability of 2G12 to
inhibit gp120-Fc-DC-SIGN interaction. Although prelim-
inary experiments indicated that gp120-Fc bound to
CEM.CD4+ cells with similar affinity as Fc-gp120 (data
not shown), Fc-gp120 bound more efficiently to DC-
SIGN than did gp120-Fc (Fig. 5A). Nevertheless, 2G12
inhibited gp120-Fc binding by an average of 70%, similar
to the inhibition observed with Fc-gp120 (Fig. 5A).
To investigate point ii), whether the discrepancy could
relate to HSPG-gp120 binding, we analyzed Fc-gp120
binding to Namalwa cells expressing either CD4, DC-
SIGN, or HSPG (Syndecan) (Fig. 5B). Like the CHO
pgsA745 cells, Namalwa cells were selected because of the
absence of HSPG expression on their surfaces. 2G12 had
very little effect on Fc-gp120 binding to CD4+ Namalwa
cells, although mAb b12 was able to inhibit, consistent
with our earlier findings (Fig. 2C). On Namalwa cells
expressing DC-SIGN, as with the CHO pgsA745 DC-
SIGN+ cells, 2G12 inhibited Fc-gp120 binding in a dose-
dependent manner (Fig 5B). However, 2G12 did not
inhibit Fc-gp120 binding to cells expressing HSPG. The
results are consistent with the role of the V3 loop rather
than the 2G12 epitope in HSPG binding [60], as verified
by a lack of binding of V3 loop-deleted Fc-gp120 to
HSPG-expressing Namalwa cells (data not shown). We
further investigated 2G12 inhibition of whole virus bind-
ing to DC-SIGN and HSPGs (Fig. 5C). Consistent with the
above results using Fc-gp120, we observed a dose-depend-
ent inhibition of HIV-1 attachment to Namalwa cells
expressing DC-SIGN, but no inhibition using cells
expressing HSPG (Fig. 5C). We conclude that the lack of
2G12 effect on Env binding to DC-SIGN previously
observed [20] may have stemmed from the masking effect
of baseline HSPG expression on the target cells. Another
study [61] reported that 2G12 did not inhibit virus attach-
ment to DC-SIGN-expressing cells. However, in that
study, 2G12 was used at 10 µg/ml, a concentration that is
just below the threshold required to inhibit gp120-DC-
SIGN binding (Fig. 5C). Overall, we have shown that
2G12 inhibits the interaction of virus with DC-SIGN
expressed on various cell types and that the virus-DC-
SIGN association can be modeled effectively, if imper-
fectly, by measuring Fc-gp120-DC-SIGN binding.
Binding of Fc-gp120 chimeras to cellular CCR5 Figure 3
Binding of Fc-gp120 chimeras to cellular CCR5. A) 
Inhibition of Fc-gp120-sCD4 complex binding to CCR5 by 
RANTES (1 µg/ml), TAK779 (0.5 µg/ml) and 2G12. Binding 
inhibition was assessed by FACS analysis and is expressed as 
a percentage calculated with reference to m.f.i. data using Fc-
gp120-sCD4 complexes alone (0% inhibition value) and back-
ground with nothing added (100% inhibition value). Results 
are the means of triplicates. B) Inhibition assays were per-
formed using Fc-gp120 complexed with 1 or 10 µg/ml of 
sCD4 and mAbs 2G12 or b12 at 10 or 25 µg/ml. Inhibition of 
binding was expressed as a percentage, as above. Results are 
the means of duplicates.
RANTES
TAK779
2G12
(µg/ml)
2.5 10 25
0
20
40
60
80
100
WT ￿V1V2
%
 
i
n
h
i
b
i
t
i
o
n
 
o
f
 
b
i
n
d
i
n
g A)
B)
0
25
50
75
100
1 µg/ml 10 µg/ml
sCD4
10 25 10 25
%
 
i
n
h
i
b
i
t
i
o
n
 
o
f
 
b
i
n
d
i
n
g
2G12 (µg/ml) b12 (µg/ml)Retrovirology 2006, 3:39 http://www.retrovirology.com/content/3/1/39
Page 7 of 15
(page number not for citation purposes)
ELISA mapping of the determinants of gp120 involved in 
DC-SIGN binding
Previously published ELISA MAb competition studies
concerning the determinants of gp120 important for DC-
SIGN interaction and unexpectedly found that V3 loop
mAbs interfered with gp120-DC-SIGN binding, but 2G12
did not [61]. However, a direct role of the V3 loop in DC-
SIGN binding is unlikely, because ∆V3 and ∆V1V2V3 Envs
2G12 neutralizes HIV-1 JR-CSF effectively in a post-CD4  assay format Figure 4
2G12 neutralizes HIV-1 JR-CSF effectively in a post-
CD4 assay format. The neutralization activity of mAbs A) 
b12, B) X5, and C) 2G12 was assessed in the standard 
(closed circles) and post-CD4 (open circles) neutralization 
formats. Results are expressed as % of residual infection, 
with 100% representing infection in the absence of mAb. 
Results are representative of two experiments.
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Effect of 2G12 on Env-HSPG and Env-DC-SIGN binding Figure 5
Effect of 2G12 on Env-HSPG and Env-DC-SIGN bind-
ing. A) The inhibitory effect of mannan (50 µg/ml) and 2G12 
Fab (25 µg/ml) and 2G12 IgG (25 µg/ml) on binding of Fc-
gp120 and gp120-Fc chimeras to CHO pgsA745 cells trans-
duced with MIGR1 GFP/DC-SIGN. Fc alone was included as 
a negative control. Data are representative of triplicates. B) 
Namalwa cells expressing either CD4, HSPGs (syndecan 2) 
or DC-SIGN were assessed for Fc-gp120 binding in the 
absence or presence of varying concentrations of mAbs b12 
and 2G12. Inhibition is expressed as a percentage of Fc-
gp120 binding compared to controls. C) Virus capture by 
Namalwa cells expressing either HSPGs or DC-SIGN was 
assessed in the absence or presence of varying concentra-
tions of mAbs b12 and 2G12. Inhibition is expressed as per-
centage of p24 captured compared to controls. Results are 
representative of two experiments.
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bind effectively to DC-SIGN-expressing cells, as probed
using CHO pgs-A745 cells (data not shown), Namalwa
cells (Fig 5), MDDCs (see below), and others [61]. Since
CHO pgsA745 and Namalwa cells are deficient in CD4,
CCR5 and HSPG receptors that might foster the binding
of V3-deleted Envs, the inhibition of gp120-DC-SIGN
binding by mAbs is a paradox worth reinvestigating. We,
thus, devised two competitive ELISA formats. In a format
similar to that reported previously [60], the V3 loop mAb
447-52D inhibited Fc-DC-SIGN binding to gp120 (not
shown), consistent with the previous report. In contrast,
2G12 was relatively ineffective and b12 had no effect.
Even mannan, used as a positive control, was only mod-
erately effective, perhaps suggesting a problem with this
format. Considering our FACS data implying that 2G12
inhibits DC-SIGN binding to gp120 (Fig. 5), these ELISA
results were unexpected. Therefore, we further investi-
gated the DC-SIGN-gp120 interaction in essentially in the
reverse ELISA format. Here, Fc-DC-SIGN was coated on
the ELISA wells, fixed concentrations of mAb competitors
were then added and biotinylated Fc-gp120 that had been
previously titrated on a separate plate was overlaid, the
binding of which was then detected using a strepatavidin-
alkaline phosphatase substrate. This format gave remark-
ably different results (Fig. 6). The IC50 of Fc-gp120 bind-
ing was ~5 ng/ml (~0.017 nM, based on a molecular
weight of ~290 kDa for Fc-gp120), an order of magnitude
higher than the IC50 the other ELISA format. In addition,
the competitive strength of mAbs and mannan were also
greater and background binding was lower. Moreover, the
competition profile was qualitatively different. Mannan
convincingly inhibited the gp120 binding to DC-SIGN, as
would be expected. In contrast to the other format, 2G12
was highly effective, and a V3 loop mAb 447-52D was
largely ineffective, as was b12 (Fig. 6). The basis for the
difference between these ELISA formats is unclear. It is
possible that the competition in the new format was
stronger due to the use of whole IgGs instead of Fabs.
However, this does not explain the qualitative differences,
especially considering that, in the new format, Fab 2G12
competition was even greater than the whole IgG (not
shown). Instead, it is likely that coating gp120 to the
ELISA plate interfered with DC-SIGN binding in the initial
ELISA format. Considering the higher affinity gp120-DC-
SIGN binding and that the competition analysis was con-
sistent with our results in Fig. 5, we suggest that the ELISA
format shown reflects the true gp120-DC-SIGN binding
relationship – partially inhibitable by 2G12, but not by
V3 loop-specific mAbs.
The relevance of mAb inhibition using primary cells
We next assessed the in vivo relevance of the modes of
2G12 inhibition using primary monocyte-derived den-
dritic cells (MDDCs) generated in-vitro. Studies of
MDDCs have emphasized the importance of mannose C-
type lectin receptors (MCLRs), particularly DC-SIGN, for
gp120 binding, and, therefore, virus uptake and dissemi-
nation to CD4+ T cells. To investigate whether 2G12 could
inhibit DCs transfer to CD4+ T cells, we performed trans-
infection experiments using primary immature MDDCs
and TZM-BL cells. TZM-BL cells are HeLa cells engineered
to express CD4 and CCR5, and to harbor a β-galactosidase
gene under the control of the HIV LTR (see materials and
methods section). As shown on Figure 7A, MAbs b12 and
2G12 effectively inhibited trans-infection of virus from
primary MDDCs. Mannan also inhibited trans-infection
by preventing virus capture on MDDCs. Thus, while b12
inhibition occurred by classic neutralization of captured
virus, the activity of 2G12 could stem from both the inhi-
bition of virus attachment via DC-SIGN, or another C-
type lectin expressed on MDDCs, as well as by blocking
virus binding to CCR5. To further investigate, we exam-
ined mAb inhibition of Fc-gp120 binding to MDDCs and
PBLs. Our results revealed that mannan, EGTA (not
shown), and 2G12 partially inhibited Fc-gp120 attach-
ment to MDDCs, the latter with an IC50 of ~20 µg/ml
(Fig. 7B), but b12 and sCD4 did not significantly inhibit
binding. In contrast, on PBLs, b12 and sCD4 were effec-
tive at inhibiting binding, and 2G12 was only partially
effective. Taken together, our results suggest that Env
2G12 inhibits DC-SIGN-gp120 interaction in ELISA Figure 6
2G12 inhibits DC-SIGN-gp120 interaction in ELISA. 
The ability of mAbs to inhibit DC-SIGN-gp120 interaction 
was evaluated. Fc-DC-SIGN was coated on the plate. Fixed 
concentrations of mAbs or mannan were then added, fol-
lowed by graded concentrations of biotinylated Fc-gp120, 
which was detected using a streptavidin-alkaline phosphatase 
conjugate. Results are representative of two independent 
assays.
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attachment via DC-SIGN or other MCLRs expressed on
MDDCs supersedes attachment by primary receptors. In
contrast, for primary PBLs, attachment appears to occur
predominantly via CD4 and CCR5.
Discussion
In the present study, we investigated mAb interference of
Env and virus attachment to various cell lines and primary
lymphocyte targets. Fc-gp120 was shown to be a relevant
tool to investigate gp120-receptor interactions without
complications of neutralization and other difficulties in
detection associated with whole virus binding assays. Fc-
gp120 has several advantages over the use of live virus, in
providing a rapid (FACS and ELISA-compatible), conven-
ient (easy to purify and detect) and safe (non-infectious)
tool for assessing of gp120-receptor interactions. ELISA
data (Fig. 1) indicated that the structural integrity of
gp120 in the Fc-gp120 chimeras was conserved and that
the Fc domain had no deleterious effects on gp120 fold-
ing. Furthermore, fusing Fc upstream of gp120 was useful,
since it allowed greater expression, compared to down-
stream fusion.
Using Fc-Env chimeras as a molecular tool, we investi-
gated gp120's interaction with its receptor, coreceptor and
attachment cofactor(s), and the inhibition mechanism of
nAbs and entry inhibitors. We observed inhibition of WT
and loop-deleted Fc-gp120 chimera binding to CD4 by
sCD4, b12 and to CCR5-expressing cells by 2G12 (Figs. 2
and 3). These results were consistent with the mAbs activ-
ities against whole virus in neutralization assays (Fig. 4).
Similarly, 2G12 inhibition of Fc-gp120-DC-SIGN paral-
leled its inhibition of virus binding to DC-SIGN (Fig. 5).
Although Fc-gp120 is a useful tool, we acknowledge that
inhibition of its binding to cells might not always predict
a biologically relevant activity against intact virus, because
conformational constraints restrict many non-neutraliz-
ing Abs from binding to trimers but not gp120 mono-
mers. For example, a non-neutralizing mAb directed to
the gp120 CD4 binding site might inhibit Fc-gp120 bind-
ing to CD4+ cells, but would not affect the interaction of
virus with CD4. Thus, inhibition of Fc-gp120 binding to
receptors may be necessary, but not be sufficient to predict
inhibition of whole virus attachment. On the other hand,
it has been recently reported that virus particles them-
selves may bear gp120/gp41 monomers [70], perhaps
increasing the relevance of Fc-gp120 as a surrogate for
viral Env. This possibility is supported by the similar inhi-
bition IC50s of Fc-gp120 and virus binding to DC-SIGN
expressing cells by 2G12 (Figs 5B and 5C). Indeed, Fc-
gp120 chimeras might provide tools for rapid and con-
venient screening of small molecule inhibitors and nAbs
able to inhibit gp120-receptor interactions that could be
useful in HIV therapies or microbicides. Indeed, for effec-
tive use in ELISA, the Fc portion, with its numerous posi-
tively charged residues, binds preferentially to microwells,
leaving gp120 free to interact with a ligand.
Our most significant findings were that 2G12 inhibits
HIV-1 by two mechanisms: blocking both gp120-CCR5
and gp120-DC-SIGN interactions. 2G12 inhibition of
gp120 binding to DC-SIGN was revealed in several dis-
tinct assays: inhibition of both Fc-gp120 and whole virus
binding to two different DC-SIGN-expressing cell lines
and inhibition of binding to recombinant DC-SIGN bind-
ing in ELISA. Previously, gp120-DC-SIGN inhibition was
Inhibition of trans-infection by MDDCs and of Fc-gp120 bind- ing to primary PBLs and MDDCs Figure 7
Inhibition of trans-infection by MDDCs and of Fc-
gp120 binding to primary PBLs and MDDCs. A) MAbs 
b12 or 2G12, or mannan were incubated with virus (10 and 
50 ng p24). The mixture was then incubated with primary 
MDCCs, followed by washing. Cells were then added on top 
of TZM-BL cells previously plated a day before, and trans-
infection was assayed two days later by a β-gal assay. Results 
are the mean values of triplicates. B) Inhibition of Fc-gp120 
binding to primary PBLs and MDDCs in the presence of 
sCD4, b12 Fab, 2G12 Fab or mannan at the concentrations 
indicated. Inhibition is expressed as the percentage of Fc-
gp120 binding.
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not observed [50,51,66]. The discrepancy probably relates
to baseline expression of HSPGs on target cells that can
also mediate Env binding. Regarding potency, 2G12
inhibited Env-DC-SIGN interaction with an IC50 of ~20
µg/ml, which is somewhat weaker than its neutralizing
IC50 (~5 µg/ml). This difference might be related to the
fact that the binding sites of 2G12, DC-SIGN, and CCR5
on Env are each unique. The CCR5 binding site of gp120
most closely approximates the epitope of CD4-induced
mAbs on gp120 [4,7,60,71], 2G12 recognizes terminal
mannose of a specific array of carbohydrates on gp120,
and DC-SIGN binds to gp120 carbohydrates in a manner
that is largely independent of specific carbohydrate arrays
[60]. Indeed, mutational analysis revealed that removal of
carbohydrates that eliminate 2G12 binding do not affect
the binding of DC-SIGN [72]. Thus, it is reasonable that
2G12 binding is only partially able to block multimeric
DC-SIGN binding [18,20,25]. This adds to the complex
and sometimes unexpected competitive relationships of
sugar-binding gp120 ligands. So far, information suggests
that cyanovirin inhibits 2G12 binding to Env [3,60], but
2G12 does not inhibit cyanovirin binding [3,7]; DC-
SIGN-Env binding does not inhibit 2G12 binding [60],
but according to present data, the reverse competition
appears to be at least partially true.
Overall, our results confirm that initial attachment of HIV
to primary cell types may or may not be CD4 dependent
[20], depending on the cell type involved. DC-SIGN
mediates a dominant role in virus attachment to MDDCs,
just as syndecans expressed on MDMs, as well as other
mannose C-type lectin receptors (MCLRs) expressed on
different DC subsets [73], most importantly the mannose
receptor on dermal DCs and langerin on epidermal lang-
erhans cells, the latters being the primary cells to capture
virus during mucosal infection [74]. Thus, DC-SIGN,
other MCLRs, and HSPGs may play parallel roles in seed-
ing virus infection, although their relative importance in
virus capture and transport to lymph nodes remains to be
fully understood [75]. Inhibiting virus-DC-SIGN/MCLRs
interaction by blocking certain determinants on gp120
may be a valid intervention strategy. Already, cyanovirin,
another inhibitor of gp120-MCLRs attachment, is being
considered as a microbicide [76]. The effects of 2G12
reported herein highlight its potential to inhibit virus dis-
semination during primary infection and support further
investigation of its possible use as a microbicide, or in
post-exposure prophylaxis [77]. Indeed, it was recently
reported that compared to other nAbs, 2G12 passive ther-
apy was relatively potent in limiting HIV resurgence in
human volunteers that ceased highly active antiretroviral
therapy [78]. It is possible that this increased potency
relates to the particular properties of 2G12 in inhibiting
trans-infection via gp120-DC-SIGN/MCLRs disruption, as
well as in neutralizing via gp120-CCR5 disruption, that
together might amplify its activity in vivo. However, it
should be noted that 2G12 does not recognize most clade
C and clade E viruses (5), and, therefore, limits its use as
an effective prophylactic agent in settings where these
viral subtypes predominate. Further studies should help
reveal the full potential of 2G12's dual mechanism of
action in inhibiting binding of gp120 to CCR5 and DC-
SIGN, and, hence, virus dissemination.
Methods
Cloning, protein expression and purification
i) Env-based proteins
Fc-gp120 chimeras were constructed by fusing an IgG1 Fc
domain N-terminal to gp120JR-CSF [42]. A series of Fc-
gp120 fusion proteins included one with full-length (wild
type; WT) gp120 and 3 that were modified to remove var-
iable loop domains: ∆V1V2 (∆129–194, according to the
amino acid numbering of the LAI isolate, replaced by a
GSG linker), ∆V3 (∆298–329, replaced by a GSGG linker)
or ∆V1V2V3 (∆129–194 + ∆298–329). For WT and V1V2-
deleted Fc-gp120s, Fc was fused in-frame to the Leu resi-
due at position 51, whereas, in V3 and V1V2V3-deleted
Fc-gp120s, Fc was fused in-frame at the Val residue at posi-
tion 74. Therefore, the first two gp120 chimeras contain
an integral C1 region, confirmed by ELISA using C1 spe-
cific antibodies (data not shown), whereas the two latter
chimeras do not, as they failed to recognize the C1 anti-
bodies. That difference, however, didn't alter the overall
conformation of gp120 as an ELISA assay using CD4-Ig2
showed a similar reactivity profile for all the Fc-gp120 chi-
meras (Figure 1B). Furthermore, a similar binding curve
was observed for all the chimeras by a FACS titration assay
using CD4+ CEM cells and primary CD4+ T cells (data not
shown). The Fc-gp120 chimeras were produced in CHO
cells using the glutamate synthetase expression system as
previously described (20). Fc-gp120 was batch purified
from culture supernatants on protein A. We also generated
chimeras where the position of gp120 and Fc was reversed
(gp120-Fc). We also generated full-length and ∆V1V2V3
(∆128–194 + ∆298–329) JR-CSF gp120 without Fc tags in
Drosophila SC2 cells using the vector pRMAH3, using
methods described previously [79].
ii) Fc-DC-SIGN
The entire ectodomain of DC-SIGN was fused in-frame
with the Fc region of IgG1. Fc-DC-SIGN was produced
using CHO cells and the glutamate synthetase amplifica-
tion system as described previously [56].
Monoclonal antibodies, sera, soluble CD4 and small 
molecule entry inhibitors
The mAbs employed in these studies included b12
(directed to an epitope overlapping the CD4 binding site
(CD4bs) of gp120) [2]; 2G12 (directed to a specific high
mannose carbohydrate cluster on gp120) [3-7]; 447-52DRetrovirology 2006, 3:39 http://www.retrovirology.com/content/3/1/39
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(directed to the gp120 V3 loop) [80]; G3-4 (directed to
the gp120 V1V2 loop) [81]; 17b and X5 (directed to
epitopes that are induced on gp120 by CD4 binding;
CD4i) [43]. In some cases, monovalent Fab fragments
were produced by papain digestion, according to manu-
facturer's instructions (Pierce). CD4-based proteins were
obtained from Progenics Pharmaceuticals: CD4-IgG2
(also known as PRO542; a fusion protein in which the
variable domains of IgG are replaced by D1D2 of CD4)
[82-84] and 4-domain recombinant soluble CD4 (sCD4).
HIVIG, a polyclonal IgG purified from pooled HIV+
donor sera, was a gift from Dr. John Mascola. The carbo-
hydrate derivatives EGTA and mannan were obtained
from Sigma. Coreceptor binding inhibitors included
RANTES (R&D systems, Minneapolis) and TAK779 (cour-
tesy of the NIH AIDS Research and Reference Reagent Pro-
gram).
ELISA
To assay the binding of a panel of mAbs and a polyclonal
serum, Fc-gp120 chimeras or monomeric gp120 were
directly coated on ELISA plates at 5 µg/ml and subsequent
steps were performed as described previously [85], except
that binding to Fc-gp120 was detected via an anti-Fab
instead of anti-Fc alkaline phosphatase conjugate, to
avoid cross-reactivity of the conjugate with the Fc portion
of Fc-gp120.
Competition ELISA to investigate gp120-DC-SIGN binding
Two ELISA formats to investigate DC-SIGN-gp120 interac-
tion were developed: i) Monomeric JR-CSF gp120 was
coated on Immulon II plates at 5 µg/ml. Fifty microliters
of Fab 447-52D, Fab b12, Fab 2G12 or mannan competi-
tors were then incubated for 30 minutes. Fabs were used
at 50 µg/ml and mannan at 100 µg/ml. Fifty microliters of
graded concentratons of Fc-DC-SIGN that had been previ-
ously titrated on a separate plate was then overlaid. Fol-
lowing washing, bound Fc-DC-SIGN was detected using
an anti-Fc alkaline phosphatase conjugate (Accurate) and
the AMPAK substrate system. ii) Fc-DC-SIGN was coated
on ELISA wells at 5 µg/ml. Fifty microliters of saturating
concentrations of 2G12, b12, 447-52D (50 µg/ml) or
mannan (100 µg/ml) competitors were then added. Bioti-
nylated Fc-gp120 that had been titrated on a separate
plate was then overlaid. Bound gp120 was then detected
using streptavidin-alkaline phosphatase conjugate (Vector
Laboratories, Burlingame, CA). All binding buffers were
supplemented with 2 mM CaCl2.
Cells
CEM cells were obtained from Douglas Richman (Univer-
sity of California, San Diego). CF2ThCD4synCCR5 and
CF2ThsynCCR5 are canine cell lines that express high lev-
els of CCR5, through a codon-optimized CCR5 gene [86].
CHO-pgsA745 cells and 293T cells co-expressing GFP and
DC-SIGN were previously described [36]. PBMC were iso-
lated from donors using Ficoll gradients. MDDCs were
produced from PBMC by MACS separation, using anti-
CD14 coated magnetic microbeads, and cultured for 6
days in RPMI supplemented with 10% FBS, 50 ng/ml of
IL-4 (Peprotech) and 50 ng/ml of GM-CSF (Peprotech).
The peripheral blood lymphocytes (PBLs) remaining from
MACS separation were cultured in parallel in RPMI sup-
plemented with 10% FBS, 5 µg/ml Concanavalin A
(Sigma) and 100 units/ml of IL-2 (NIH AIDS Research
and Reference Reagent Program) and both cell fractions
from donors were used in binding assays. Namalwa cells,
a human B cell parental line, engineered to express either
CD4, HSPG (syndecan-2) or DC-SIGN were previously
described [20,42]. TZM-BL cells (also known as JC53-BL
cells) were used as target cells for pseudovirus infection
assays. TZM-BL is a HeLa cell clone that expresses CD4,
CXCR4 and CCR5 and contains Tat-responsive reporter
genes for firefly luciferase and β-galactosidase under the
control of a HIV long terminal repeat [87].
Analysis of Fc-gp120 attachment to target cells by FACS
To analyze binding of Fc-gp120 chimeras to target cells,
Fc-gp120 was incubated at 1 µg/ml with 2 × 105 cells for
one hr at room temperature (RT) in 100 µl of Earl's Bal-
anced Salt Solution (EBSS, Sigma, St. Louis, MO) contain-
ing 0.1% bovine serum albumin (BSA, Sigma), washed
once in EBSS and resuspended in 100 µl of EBSS/0.1%
BSA supplemented with a phycoerythrin conjugated anti-
human Fc antibody (ICN-Cappel, Aurora, OH) at a 1:250
dilution. Samples were then washed and processed on a
FACScan (Beckton Dickinson, San Jose, CA). Data were
acquired and analyzed with Cellquest (Beckton Dickin-
son) and FlowJo (Tree Star, San Carlos, CA) software,
respectively. For gp120/DC-SIGN interaction, CaCl2 was
added at a final concentration of 2 mM in the incubation
and wash buffers. For gp120/CCR5 interaction, Fc-gp120
was pre-incubated with sCD4 for 30 min at RT. For inhi-
bition studies, Fc-gp120 chimeras were pre-incubated
with the inhibitor at RT (unless otherwise noted), then the
mixture was added to target cells. In the case of RANTES
and TAK-779, cells were also pre-treated in parallel for 30
min at the indicated concentration. For mAb inhibition,
we used Fab fragments. Percent inhibition was calculated
by the formula 100 - [(t - c)/(m - c) × 100], where t repre-
sents the signal for the test sample, c represents the back-
ground signal in the absence of Fc-gp120, and m
represents the signal obtained for Fc-gp120 in the absence
of inhibitor.
Neutralization and attachment assays
In a series of attachment and neutralization assays, we
employed JR-CSF pseudovirus as well as live virus to
investigate the activity of DC-SIGN and 2G12. In method
i) pseudoviruses were used, produced as described previ-Retrovirology 2006, 3:39 http://www.retrovirology.com/content/3/1/39
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ously by transfection of 293T cells with pNL4-3.Luc.R-E-
and HIV-1JR-CSF Env-expressing plasmids [86,88]. In meth-
ods ii) and iii), live viruses harvested after transfection of
293T cells were used [42].
i) Standard and post-CD4 neutralization assays
Briefly, virus was incubated with cells for 2 h. Luciferase
activity was measured as described previously [88]. Neu-
tralization was measured in two formats with all incuba-
tions at 37°C. In the standard neutralization assay format
[46], virus was incubated with graded concentrations of
inhibitor for 1 h before transferring to CF2Th.CD4.CCR5
cells for a further 2 h incubation, including a 15 minute
spinoculation step to increase the assay sensitivity. In the
"post-CD4 binding" neutralization format, we preincu-
bated pseudovirions with sCD4 (10 µg/ml) for 15 min-
utes. Next, the virus-sCD4 cocktail was mixed with graded
amounts of mAb for 1 h then allowed to infect
Cf2Th.CCR5 cells by spinoculation. All assays were per-
formed at least in duplicate and were repeated for a total
of at least 4 replicates to ensure consistency.
ii) Neutralization of trans-infection
Briefly, virus corresponding to 10 or 50 ng p24 was incu-
bated with mAbs for 1 hr at RT then added to MDDCs,
incubated another 2 h with mixing every 30 min, then the
cells were washed 3 times and finally added to TZM-BL
cells. After 48 hours co-culture, trans-infection of TZM-BL
cells was assayed by a β-gal assay. Results are expressed as
% inhibition of infection. As a control, MDDCs were incu-
bated with virus in the absence of nAbs.
iii) Inhibition of virus attachment to cells
Inhibition of virus attachment to cells was assessed using
a method described previously [42]. Virus (1 ng p24) was
pre-incubated (1 h at RT) with b12 or 2G12 at graded con-
centrations. Virus-mAb mixtures were then added to
Namalwa cells (0.25 × 106/500 µl complete RPMI) for 2
hrs at 37°C. Cells were next washed three times in PBS,
lysed in triton X-100 and p24 content measured by ELISA.
Under these conditions, no internalization occurs, since
no cytosolic p24 can be detected upon protease treatment
of the target cells, as previously described [19]. Percent
inhibition was calculated, as for the FACS analysis.
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